PEMF for
Post-Herpetic Neuralgia.

July 2026 · 10 min read · Neuropathic Pain Protocol

Post-Herpetic Neuralgia: The Disease the Pharmacopoeia Has Not Solved

Post-herpetic neuralgia (PHN) is defined as pain persisting beyond 3 months after herpes zoster (shingles) rash resolution. It is caused by varicella-zoster virus (VZV) reactivation in the dorsal root ganglia, which triggers a cascade of neural injury: axonal degeneration, loss of large inhibitory A-β fibers, ectopic discharge from injured C-fibers, and central sensitization in the dorsal horn — the same mechanism that underlies complex regional pain syndrome.

Three pain types coexist in PHN and each responds differently to treatment:

• Burning/aching background pain: continuous, from spontaneous C-fiber discharge in the injured dermatome
• Allodynic hypersensitivity: light touch, clothing, or air movement triggers severe pain (loss of A-β inhibitory gating)
• Shooting/stabbing pain: episodic, from ectopic discharge bursts in deafferented neurons

Current first-line treatments — gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, and opioids — achieve meaningful pain relief in only 30–50% of PHN patients and carry significant tolerability problems, particularly in the elderly (sedation, falls, cognitive decline, dependency). PHN remains one of the most refractory chronic pain conditions in geriatric medicine.

The Philippine PHN Landscape

Varicella-zoster seroprevalence in Filipino adults exceeds 90%, representing a latent reservoir of 70 million+ at risk for reactivation. Herpes zoster incidence rises sharply with age and immunosenescence:

Estimated total new PHN cases in the Philippines: 90,000–180,000 annually. PHN pain persists for months to years. Only 6% of Filipino adults over 60 have received herpes zoster vaccine (Shingrix), and most patients present to physicians after the 72-hour antiviral treatment window, limiting acute outbreak management. This creates a large, poorly managed chronic pain cohort that PEMF clinics are positioned to serve.

How PEMF Addresses PHN Pathophysiology

PEMF targets three of the four PHN pain mechanisms with peer-reviewed mechanistic support:

1. Neuroinflammation suppression: Deafferentation after VZV nerve injury triggers persistent perineural NF-κB activation, sustaining IL-1β and TNF-α production in the dorsal horn. PEMF suppresses NF-κB, IL-1β, and TNF-α in soft tissue and nerve sheaths (Strauch 2009, PubMed 19371845) — directly reducing the inflammatory driver of spontaneous pain and allodynia.
2. Intraneural microcirculation and angiogenesis: VZV reactivation damages the intraneural blood supply, creating ischemic segments in injured nerve fibers. PEMF upregulates nitric oxide via eNOS (PubMed 31394939) and VEGF (PMC4959873) — restoring intraneural blood flow and promoting axonal repair in surviving nerve fibers.
3. Peripheral nerve conduction normalization: In the CTS nerve entrapment model (PMC5144749/PMID 27980864, n=40, 4 weeks), PEMF at 50 Hz, 8 mT, 30 min, 3×/week significantly improved sensory and motor nerve conduction latency and velocity vs. ultrasound across all endpoints (p<0.05). PHN involves a similar peripheral nerve conduction deficit — demyelination and axonal loss in the affected dermatome.

The fourth mechanism — reduction of central sensitization — is addressed indirectly through peripheral inflammatory load reduction. PHN's allodynic component (loss of A-β gating) is the most challenging aspect and requires lower-frequency, lower-intensity PEMF to avoid triggering the sensitized system.

The Evidence Base for PEMF in Neuropathic Pain

No dedicated PHN-PEMF randomized controlled trial has been published. Clinical evidence is extrapolated from the broader neuropathic pain evidence base, with explicit framing of that extrapolation:

• 2026 Meta-analysis (PMC12943413, 13 RCTs, N=688): PEMF for neuropathic pain overall SMD=–1.01 (95%CI –1.40 to –0.62, p<0.001) — the largest neuropathic pain meta-analysis to date. This includes peripheral neuropathy conditions sharing PHN's deafferentation and ectopic discharge mechanisms.
• RELIEF Trial (PMC11874150, n=182, double-blind, 18 sites): PEMF for diabetic peripheral neuropathy: 30% overall pain reduction; 85% vs. 25% in the compliant treatment subgroup. Protocol: 27.12 MHz, 42 µs, 1,000 pps, 30 min 2×/day, 18 weeks. DPN shares PHN's peripheral nerve degeneration pathway.
• Peripheral nerve conduction (PMC5144749, PMID 27980864, n=40): PEMF superior to ultrasound across all nerve conduction study endpoints including sensory latency, motor latency, conduction velocity, and grip strength (all p<0.05, 4 weeks). The peripheral nerve repair mechanism is directly relevant to PHN's demyelination and axonal loss.
• SSEP improvement (PMID 23083041, n=40): In lumbar radiculopathy, PEMF significantly improved somatosensory evoked potential latency (p=0.016/0.022) and amplitude (p=0.001/0.002) — confirming that PEMF acts at the neural conduction level, not just pain perception.

Three-Phase Clinical Protocol

Critical pre-treatment requirement: Active zoster rash is a contraindication to direct PEMF application over the affected dermatome. Confirm rash resolution (typically 2–4 weeks post-onset) before initiating PEMF. In early PHN (rash resolved but pain established), begin with Phase 1 proximal protocol.

Session frequency: 2–3 per week for Phases 1–2; reduce to 1–2 per week in Phase 3. Full course: 24 sessions over 10–12 weeks. For long-duration PHN (12+ months), extend to 30 sessions. Maintenance: 2–4 sessions/month for chronic PHN with established central sensitization.

Allodynia management protocol: If direct dermatomal application triggers pain amplification, retreat to proximal-only placement and reduce intensity. Never force progression — a slower titration produces better long-term outcomes in allodynic PHN than rapid exposure.

PEMF vs. Standard PHN Pharmacotherapy

Patient Selection Criteria

PEMF is most valuable for PHN patients in the following clinical situations:

• Gabapentinoid-intolerant patients: elderly patients (65+) experiencing sedation, dizziness, or fall risk with gabapentin/pregabalin — a common reason for dose reduction or discontinuation
• Partial responders to pharmacotherapy: patients on gabapentin or amitriptyline with residual pain VAS >4/10 — PEMF added as an adjunct reduces the neuroinflammatory load that drugs alone cannot address
• Post-acute PHN (3–12 months): the window when peripheral mechanisms still predominate and PEMF's nerve repair action is most impactful
• Long-duration PHN (>12 months) with allodynia: requires the modified low-frequency, proximal-first protocol — outcomes are more modest but functional improvement (clothing tolerance, sleep quality) is meaningful
• Thoracic PHN (T3–T10 dermatomes): the most common zoster distribution in elderly patients; coil placement over the posterior thoracic spine targets the affected dorsal root ganglia level

Contraindications: active pacemaker, implanted neurological stimulator, pregnancy. Do not apply PEMF over active zoster rash. Confirm malignancy has been excluded in patients with atypical distribution or systemic symptoms (disseminated zoster may indicate lymphoma).

The Market Case: Why PHN Belongs in Your PEMF Clinic

PHN patients are among the highest-lifetime-value patient segments for PEMF clinics. They are chronic — many manage pain for 12–36 months. They are drug-weary — after failing gabapentin or experiencing intolerable side effects, they actively seek alternatives. And they are able to pay — they are typically employed or professionally retired adults aged 50–75 who self-fund treatment rather than wait for limited public health rehabilitation slots.

A single PHN patient completing a 24-session course generates ₱36,000–₱60,000 in clinic revenue. Maintenance patients returning 2–4 sessions/month generate a recurring annuity of ₱36,000–₱120,000/year. With 90,000–180,000 new PHN cases annually in the Philippines — a number that will grow as the population ages — this is a sustainable, growing patient population that currently has nowhere effective to go.

Frequently Asked Questions

Can PEMF cure post-herpetic neuralgia?

PEMF does not cure PHN — no current treatment does. The biological goal is to reduce ongoing neuroinflammation, support residual nerve fiber repair, and reduce the peripheral input that drives central sensitization. Clinically, the target is meaningful reduction in allodynia and burning pain severity, improved sleep, and improved quality of life. Some patients in early PHN (3–6 months) with predominantly peripheral mechanisms experience durable improvement. Patients with long-standing central sensitization benefit most from ongoing maintenance treatment.

How does PEMF work alongside gabapentin — should patients taper their medication?

PEMF is additive to pharmacotherapy, not a replacement. Medication tapering, if clinically appropriate, should be managed by the prescribing physician based on patient response over multiple weeks. PEMF has no pharmacological interaction with gabapentin, pregabalin, or tricyclics. Patients often report that PEMF allows them to achieve adequate pain control at lower drug doses, but medication management remains the physician's remit.

Which zoster location responds best to PEMF?

Thoracic PHN (T3–T10) responds well due to accessible coil placement over the posterior thoracic spine at the affected dermatomal level. Trigeminal PHN (V1 ophthalmic distribution — around the eye and forehead) requires specialized coil placement and ophthalmological co-management. Lumbar/sacral PHN responds comparably to thoracic PHN. Disseminated PHN is less amenable to focused dermatomal PEMF but benefits from systemic protocols targeting the spinal pain processing level.